STRATEC RECEIVES VALIDATION OF ITS CLIMATE TARGETS FROM THE SCIENCE BASED TARGETS INITIATIVE (SBTi)

Birkenfeld, March 14, 2025

STRATEC SE, Birkenfeld, Germany, (Frankfurt: SBS; Prime Standard, SDAX) today announces the validation of its short-term and long-term greenhouse gas emission reduction targets by the Science Based Targets initiative (SBTi). STRATEC’s newly revised and science-based climate targets are thus consistent with the target set by the Paris Agreement of limiting global warming if possible to 1.5°C. The targets validated by the SBTi are as follows:

Short-term targets
The short-term target provides for reducing absolute greenhouse gas emissions in Scope 1, Scope 2, and Scope 3 by 50.4% in each case by 2032 compared with the 2023 base year.

Long-term targets
Reduction in absolute Scope 1 and Scope 2 greenhouse gas emissions by 90% by 2045 compared with the 2023 base year. Furthermore, it is also planned to reduce absolute Scope 3 greenhouse gas emissions by 90% over the same period.

Net zero target
STRATEC is committed to achieving net zero greenhouse gas emissions throughout its value chain by 2045.

“Sustainability is firmly embedded in our corporate strategy and we are determined to take proactive measures to further reduce our greenhouse gas emissions. The validation of our revised climate targets in line with the SBTi’s Net-Zero Standard is an important milestone for our sustainability strategy and confirms the path we have taken to date. We are determined to cooperate closely with our customers and suppliers and support them in decarbonizing their business models”, comments Marcus Wolfinger, CEO of STRATEC SE.

ABOUT SBTi
The Science Based Targets initiative (SBTi) is a partnership between the CDP (Climate Disclosure Project), the Global Compact of the United Nations, the World Resources Institute (WRI), and the World Wide Fund for Nature (WWF). The SBTi defines and promotes best practices for setting science-based targets and independently evaluates the targets set by companies. Further information is available at: https://sciencebasedtargets.org

ABOUT STRATEC
STRATEC SE (www.stratec.com) designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and life sciences. Furthermore, the company offers complex consumables for diagnostic and medical applications. For its analyzer systems and consumables, STRATEC covers the entire value chain – from development to design and production through to quality assurance.

The partners market the systems, software and consumables, in general together with their own reagents, as system solutions to laboratories, blood banks and research institutes around the world. STRATEC develops its products on the basis of patented technologies.

Shares in the company (ISIN: DE000STRA555) are traded in the Prime Standard segment of the Frankfurt Stock Exchange and are listed in the SDAX select index of the German Stock Exchange.

FURTHER INFORMATION IS AVAILABLE FROM:
STRATEC SE
Jan Keppeler, CFA | Investor Relations, Sustainability & Corporate Communications
Tel: +49 7082 7916-6515
ir@stratec.com
www.stratec.com